-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25

Benzinga·04/29/2026 10:42:20
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $19 to $25.